Your browser doesn't support javascript.
loading
Prognostic understanding, quality of life and mood in patients undergoing hematopoietic stem cell transplantation.
El-Jawahri, A; Traeger, L; Kuzmuk, K; Eusebio, J; Vandusen, H; Keenan, T; Shin, J; Gallagher, E R; Greer, J A; Pirl, W F; Jackson, V A; Ballen, K K; Spitzer, T R; Graubert, T A; McAfee, S; Dey, B; Chen, Y-B A; Temel, J S.
Afiliación
  • El-Jawahri A; 1] Department of Hematology Oncology-Bone Marrow Transplant Program, Massachusetts General Hospital, Boston, MA, USA [2] Harvard Medical School, Boston, MA, USA.
  • Traeger L; 1] Department of Hematology Oncology-Bone Marrow Transplant Program, Massachusetts General Hospital, Boston, MA, USA [2] Harvard Medical School, Boston, MA, USA.
  • Kuzmuk K; Department of Hematology Oncology-Bone Marrow Transplant Program, Massachusetts General Hospital, Boston, MA, USA.
  • Eusebio J; 1] Department of Hematology Oncology-Bone Marrow Transplant Program, Massachusetts General Hospital, Boston, MA, USA [2] Harvard Medical School, Boston, MA, USA.
  • Vandusen H; 1] Department of Hematology Oncology-Bone Marrow Transplant Program, Massachusetts General Hospital, Boston, MA, USA [2] Harvard Medical School, Boston, MA, USA.
  • Keenan T; 1] Department of Hematology Oncology-Bone Marrow Transplant Program, Massachusetts General Hospital, Boston, MA, USA [2] Harvard Medical School, Boston, MA, USA.
  • Shin J; 1] Department of Hematology Oncology-Bone Marrow Transplant Program, Massachusetts General Hospital, Boston, MA, USA [2] Harvard Medical School, Boston, MA, USA.
  • Gallagher ER; 1] Department of Hematology Oncology-Bone Marrow Transplant Program, Massachusetts General Hospital, Boston, MA, USA [2] Harvard Medical School, Boston, MA, USA.
  • Greer JA; 1] Department of Hematology Oncology-Bone Marrow Transplant Program, Massachusetts General Hospital, Boston, MA, USA [2] Harvard Medical School, Boston, MA, USA.
  • Pirl WF; 1] Department of Hematology Oncology-Bone Marrow Transplant Program, Massachusetts General Hospital, Boston, MA, USA [2] Harvard Medical School, Boston, MA, USA.
  • Jackson VA; 1] Department of Hematology Oncology-Bone Marrow Transplant Program, Massachusetts General Hospital, Boston, MA, USA [2] Harvard Medical School, Boston, MA, USA.
  • Ballen KK; 1] Department of Hematology Oncology-Bone Marrow Transplant Program, Massachusetts General Hospital, Boston, MA, USA [2] Harvard Medical School, Boston, MA, USA.
  • Spitzer TR; 1] Department of Hematology Oncology-Bone Marrow Transplant Program, Massachusetts General Hospital, Boston, MA, USA [2] Harvard Medical School, Boston, MA, USA.
  • Graubert TA; 1] Department of Hematology Oncology-Bone Marrow Transplant Program, Massachusetts General Hospital, Boston, MA, USA [2] Harvard Medical School, Boston, MA, USA.
  • McAfee S; 1] Department of Hematology Oncology-Bone Marrow Transplant Program, Massachusetts General Hospital, Boston, MA, USA [2] Harvard Medical School, Boston, MA, USA.
  • Dey B; 1] Department of Hematology Oncology-Bone Marrow Transplant Program, Massachusetts General Hospital, Boston, MA, USA [2] Harvard Medical School, Boston, MA, USA.
  • Chen YB; 1] Department of Hematology Oncology-Bone Marrow Transplant Program, Massachusetts General Hospital, Boston, MA, USA [2] Harvard Medical School, Boston, MA, USA.
  • Temel JS; 1] Department of Hematology Oncology-Bone Marrow Transplant Program, Massachusetts General Hospital, Boston, MA, USA [2] Harvard Medical School, Boston, MA, USA.
Bone Marrow Transplant ; 50(8): 1119-24, 2015 Aug.
Article en En | MEDLINE | ID: mdl-25961772
ABSTRACT
Little is known about how patients undergoing hematopoietic stem cell transplantation (HCT) and their family caregivers (FC) perceive their prognosis. We examined prognostic understanding in patients undergoing HCT and their FC and its relationship with quality of life (QOL) and mood. We conducted a longitudinal study of patients (and FC) hospitalized for HCT. We used a questionnaire to measure participants' prognostic understanding and asked the oncologists to estimate patients' prognosis prior to HCT. We assessed QOL and mood weekly and evaluated the relationship between prognostic understanding, and QOL and mood using multivariable linear mixed models. We enrolled 90 patients undergoing (autologous (n=30), myeloablative (n=30) or reduced intensity allogeneic (n=30)) HCT. About 88.9% of patients and 87.1% of FC reported it is 'extremely' or 'very' important to know about prognosis. However, 77.6% of patients and 71.7% of FC reported a discordance and more optimistic prognostic perception compared to the oncologist (P<0.0001). Patients with a concordant prognostic understanding with their oncologists reported worse QOL (ß=-9.4, P=0.01) and greater depression at baseline (ß=1.7, P=0.02) and over time ((ß=1.2, P<0.0001). Therefore, Interventions are needed to improve prognostic understanding, while providing patients with adequate psychological support.
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Asunto principal: Calidad de Vida / Trasplante de Células Madre Hematopoyéticas / Neoplasias Hematológicas / Afecto / Depresión Tipo de estudio: Observational_studies / Prognostic_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Bone Marrow Transplant Asunto de la revista: TRANSPLANTE Año: 2015 Tipo del documento: Article País de afiliación: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Asunto principal: Calidad de Vida / Trasplante de Células Madre Hematopoyéticas / Neoplasias Hematológicas / Afecto / Depresión Tipo de estudio: Observational_studies / Prognostic_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Bone Marrow Transplant Asunto de la revista: TRANSPLANTE Año: 2015 Tipo del documento: Article País de afiliación: Estados Unidos